HK1211479A1 - Prophylactic or therapeutic drug for constipation - Google Patents

Prophylactic or therapeutic drug for constipation

Info

Publication number
HK1211479A1
HK1211479A1 HK15112295.0A HK15112295A HK1211479A1 HK 1211479 A1 HK1211479 A1 HK 1211479A1 HK 15112295 A HK15112295 A HK 15112295A HK 1211479 A1 HK1211479 A1 HK 1211479A1
Authority
HK
Hong Kong
Prior art keywords
constipation
prophylactic
therapeutic drug
therapeutic
drug
Prior art date
Application number
HK15112295.0A
Other languages
English (en)
Chinese (zh)
Inventor
山本大輔
井尾房代
山本浩二
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of HK1211479A1 publication Critical patent/HK1211479A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
HK15112295.0A 2013-02-04 2015-12-15 Prophylactic or therapeutic drug for constipation HK1211479A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013019754 2013-02-04
PCT/JP2014/052465 WO2014119787A1 (ja) 2013-02-04 2014-02-03 便秘症の予防又は治療薬

Publications (1)

Publication Number Publication Date
HK1211479A1 true HK1211479A1 (en) 2016-05-27

Family

ID=51262485

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112295.0A HK1211479A1 (en) 2013-02-04 2015-12-15 Prophylactic or therapeutic drug for constipation

Country Status (18)

Country Link
US (1) US10022389B2 (ko)
EP (1) EP2952206B1 (ko)
JP (1) JP5807767B2 (ko)
KR (1) KR102078433B1 (ko)
CN (1) CN104955481B (ko)
AU (1) AU2014213251B2 (ko)
BR (1) BR112015017541A2 (ko)
CA (1) CA2899834C (ko)
ES (1) ES2694110T3 (ko)
HK (1) HK1211479A1 (ko)
IL (1) IL240192A (ko)
MX (1) MX346453B (ko)
MY (1) MY176162A (ko)
PH (1) PH12015501696A1 (ko)
RU (1) RU2648467C2 (ko)
SG (2) SG11201506047PA (ko)
TW (1) TWI659739B (ko)
WO (1) WO2014119787A1 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019142774A (ja) * 2016-06-20 2019-08-29 大正製薬株式会社 腸内環境改善剤

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2830424C3 (de) * 1978-07-11 1982-04-15 Bayer Ag, 5090 Leverkusen alpha -Glucosidase-Inhibitoren
US5651988A (en) 1995-08-18 1997-07-29 Xyrofin Oy Combination osmotic and bulk forming laxatives
DE60332743D1 (de) 2002-08-08 2010-07-08 Kissei Pharmaceutical Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
JP4606876B2 (ja) 2002-08-27 2011-01-05 キッセイ薬品工業株式会社 ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
CN1744916A (zh) 2002-12-04 2006-03-08 橘生药品工业株式会社 预防和治疗高血糖所导致的疾病
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
TWI387454B (zh) * 2004-09-02 2013-03-01 Sucampo Ag 治療胃腸道疾病之方法及組成物
AU2007252432B2 (en) 2006-05-19 2011-11-17 Taisho Pharmaceutical Co., Ltd. C-phenyl glycitol compound
MX2008016231A (es) 2006-06-29 2009-01-16 Taisho Pharma Co Ltd Compuesto de c-fenil 1-tioglucitol.
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法
WO2008072726A1 (ja) 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. 1-フェニル 1-チオ-d-グルシト-ル誘導体
GB2447067A (en) * 2007-02-20 2008-09-03 Branko R Babic Alteration of osmotic gradients by polyhydroxy compounds
CN101910189B (zh) 2007-12-27 2013-06-19 橘生药品工业株式会社 吡唑衍生物的单癸二酸盐
ES2385185T3 (es) 2008-04-16 2012-07-19 Kissei Pharmaceutical Co., Ltd. Hemifumarato de un derivado de pirazol
US8466113B2 (en) * 2009-02-23 2013-06-18 Taisho Pharmaceutical Co., Ltd. 4-isopropylphenyl glucitol compounds as SGLT1 inhibitors
JP2013224263A (ja) 2010-08-19 2013-10-31 Taisho Pharmaceutical Co Ltd 4−イソプロピルフェニルグルシトール化合物
RU2013112368A (ru) 2010-08-20 2014-09-27 Тайсо Фармасьютикал Ко., Лтд. Кристаллическая форма 4-изопропилфенилглюцитольного соединения и способ ее получения
EP2607360B1 (en) 2010-08-20 2015-08-19 Taisho Pharmaceutical Co., Ltd. 4-Isopropyl-6-methoxyphenyl glucitol compound
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
US9273085B2 (en) 2012-05-07 2016-03-01 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative and use thereof for medical purposes
DK3489226T3 (da) * 2012-11-20 2021-04-26 Lexicon Pharmaceuticals Inc Hæmmere for natriumglucose-cotransporter 1

Also Published As

Publication number Publication date
RU2648467C2 (ru) 2018-03-26
PH12015501696B1 (en) 2015-10-12
CA2899834A1 (en) 2014-08-07
EP2952206A4 (en) 2016-06-15
MX346453B (es) 2017-03-17
US10022389B2 (en) 2018-07-17
MX2015010029A (es) 2015-10-30
CN104955481B (zh) 2017-10-24
TW201517903A (zh) 2015-05-16
EP2952206A1 (en) 2015-12-09
AU2014213251B2 (en) 2017-07-20
PH12015501696A1 (en) 2015-10-12
JP5807767B2 (ja) 2015-11-10
SG11201506047PA (en) 2015-09-29
US20150374735A1 (en) 2015-12-31
CN104955481A (zh) 2015-09-30
IL240192A (en) 2017-03-30
KR20150112949A (ko) 2015-10-07
AU2014213251A1 (en) 2015-08-27
JPWO2014119787A1 (ja) 2017-01-26
EP2952206B1 (en) 2018-10-24
RU2015137671A (ru) 2017-03-10
MY176162A (en) 2020-07-24
CA2899834C (en) 2020-09-01
BR112015017541A2 (pt) 2017-07-11
ES2694110T3 (es) 2018-12-18
KR102078433B1 (ko) 2020-02-17
TWI659739B (zh) 2019-05-21
IL240192A0 (en) 2015-09-24
SG10201700267PA (en) 2017-02-27
WO2014119787A1 (ja) 2014-08-07

Similar Documents

Publication Publication Date Title
HRP20180684T1 (hr) Kombinacija lijekova
ZA201507576B (en) Pharmaceutical combination drug
GB201308440D0 (en) Therapeutic
HK1223833A1 (zh) 藥物劑型
ZA201600027B (en) Pharmaceutical preparation
EP3046556A4 (en) Combination drug therapy
EP2968179A4 (en) RETARD-PRESENTATIONS
GB201318668D0 (en) Sonosensitive therapeutic
HK1220633A1 (zh) 含有氨基吡唑衍生物的藥物製劑
HK1211479A1 (en) Prophylactic or therapeutic drug for constipation
ZA201506465B (en) Pharmaceutical preparation
GB201320786D0 (en) Medicament
GB201316662D0 (en) Pharmaceutical Combination
GB201305073D0 (en) Therapeutic means

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230131